clinical trial · NCT05886920
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd·phase2·active not recruiting·n = 67
Advanced Solid Tumors With MAPK Pathway MutationsD3S-002D3S-001
brief summary
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
started
Jul 10, 2023
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Mar 23, 2026
official title
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol